{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:08Z","timestamp":1791976508932,"version":"4.4.0"},"reference-count":66,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100007658","name":"Baxter Healthcare Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007658","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.2217\/imt.14.34","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T17:47:22Z","timestamp":1401904042000},"page":"553-567","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":58,"title":["Overview of Recombinant Human Hyaluronidase-facilitated Subcutaneous Infusion of IgG in Primary Immunodeficiencies"],"prefix":"10.1080","volume":"6","author":[{"given":"Richard L","family":"Wasserman","sequence":"first","affiliation":[{"name":"DallasAllergyImmunology,\r7777 Forest Lane, Suite B-332,\rDallas,\rTX,\r75230,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,6,4]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.10.013"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9751-7"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-007-9103-1"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9740-x"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2004.02.002"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.08.033"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e3181eba6ea"},{"issue":"5","key":"e_1_3_3_10_1","first-page":"504","article-title":"Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions","volume":"67","author":"Daly PB","year":"1991","unstructured":"Daly PB , EvansJH, KobayashiRHet al. Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions . Ann. Allergy67(5),504\u2013510 (1991).","journal-title":"Ann. Allergy"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90346-1"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2648.1995.21050917.x"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1993.tb03380.x"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.053"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.79.1.48"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-006-9031-5"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-006-8905-x"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.06.021"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2010.06.012"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.4.4.427"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.50.3.327"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5560040902"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1391"},{"key":"e_1_3_3_24_1","unstructured":"Hascall VC LaurentT . Hyaluronan: structure and physical properties . http:\/\/www.glycoforum.gr.jp\/science\/hyaluronan\/HA01\/HA01E.html"},{"key":"e_1_3_3_25_1","first-page":"61","volume-title":"Proteoglycans: Structure, Biology and Molecular Interactions.","author":"Toole BP","year":"2000","unstructured":"Toole BP . Hyaluronans . In : Proteoglycans: Structure, Biology and Molecular Interactions.IozzoR (Ed.). Marcel Dekker, NY, USA, 61\u201392 (2000)."},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0945-053X(01)00172-X"},{"key":"e_1_3_3_27_1","unstructured":"Vitrase\u00ae prescribing information. ISTA Pharmaceuticals CA USA (2012)."},{"key":"e_1_3_3_28_1","unstructured":"Amphadase\u00ae prescribing information. Amphastar Pharmaceuticals Inc. CA USA (2012)."},{"key":"e_1_3_3_29_1","unstructured":"Hylenex\u00ae prescribing information. Halozyme Therapeutics Inc. CA USA (2012)."},{"key":"e_1_3_3_30_1","unstructured":"Woodcock J. US FDA Department of Health and Human Services. Follow-on protein products (26March2007). http:\/\/www.hhs.gov\/asl\/testify\/2007\/04\/t20070326a.html"},{"key":"e_1_3_3_31_1","unstructured":"HyQvia (100 mg\/ml solution for infusion for subcutaneous use) summary of product characteristics. Baxter Innovations GmbH; Vienna Austria; 2013. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002491\/WC500143851.pdf"},{"key":"e_1_3_3_32_1","first-page":"6","volume-title":"American Diabetes Association 68th Scientific Sessions","author":"Yocum RC","year":"2008","unstructured":"Yocum RC , SugarmanB, VaughnD, VickA, BrunelleR, FrostG. Pharmacokinetics and glucodynamics of an insulin analog and regular insulin injected with recombinant human hyaluronidase: fast-acting insulins made faster. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6-10June2008."},{"issue":"1","key":"e_1_3_3_33_1","first-page":"1","article-title":"Hyaluronidase in ophthalmology","volume":"12","author":"Silverstein SM","year":"2012","unstructured":"Silverstein SM , GreenbaumS, SternR . Hyaluronidase in ophthalmology . J. Appl. Res.12(1),1\u201313 (2012).","journal-title":"J. Appl. Res."},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2006.05.027"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.02.035"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2009.00593.x"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.4097\/kjae.2011.60.1.57"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0470"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-012-0065-3"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3588"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903432900"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.03.009"},{"key":"e_1_3_3_43_1","unstructured":"Halozyme Pipeline. http:\/\/www.halozyme.com\/Products-And-Pipeline\/Pipeline\/default.aspx"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2010.076828"},{"key":"e_1_3_3_45_1","unstructured":"Subcuvia 160 g\/l solution for injection (human normal immunoglobulin) summary of product characteristics ; Baxter AG ; Vienna Austria ; 2011 . www.ecomm.baxter.com\/ecatalog\/loadResource.do?bid=54579"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.04027.x"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9512-z"},{"key":"e_1_3_3_48_1","first-page":"7","volume-title":"First International Primary Immunodeficiencies Congress","author":"Stein M","year":"2013","unstructured":"Stein M , WassermanRL, MelamedIet al. Tolerability\/efficacy\/pharmacokinetics of facilitated-subcutaneous infusion of human immune globulin G, 10%, and recombinant human hyaluronidase in adults with primary immunodeficiency: Phase 3 study. Presented at: First International Primary Immunodeficiencies Congress. Estoril, Portugal, 7-8November2013."},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-006-9025-3"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-006-9021-7"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04195.x"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-010-9423-4"},{"key":"e_1_3_3_53_1","unstructured":"US Food and Drug Administration . Guidance for Industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. Version 1 March2003. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070124.pdf"},{"key":"e_1_3_3_54_1","volume-title":"American Association of Asthma, Allergy and Immunology Annual Meeting","author":"Melamed I","year":"2014","unstructured":"Melamed I , WassermanRL, SteinMet al. Long-term tolerability and safety of facilitated-subcutaneous infusion of human immune globulin G (IgG), 10%, and recombinant human hyaluronidase (rHuPH20) (IGHy): a Phase 3 extension study in patients with primary immunodeficiencies (PIs). Presented at: American Association of Asthma, Allergy and Immunology Annual Meeting. CA, USA, 28February-4March2014 ."},{"key":"e_1_3_3_55_1","volume-title":"13th Biennial Meeting of the European Society for Immunodefiencies.","author":"Schiff R","year":"2008","unstructured":"Schiff R , WassermanRL, SteinMet al. Recombinant human hyaluronidase facilitates dispersion of subcutaneously administered Gammagard Liquid, enabling administration of full monthly dose in single site with improved bioavailability in immunodeficient patients. Presented at:13th Biennial Meeting of the European Society for Immunodefiencies.\u2019s-Hertogenbosch, The Netherlands, 16-19October2008."},{"key":"e_1_3_3_56_1","volume-title":"American Academy of Allergy, Asthma and Immunology Annual Meeting.","author":"Rojavin M","year":"2013","unstructured":"Rojavin M , LandersdorferC, BexonM, PfisterM, SidhuJ. Switching from monthly intravenous to biweekly subcutaneous immunoglobulin: a pharmacokinetic modeling and simulation approach. Presented at: American Academy of Allergy, Asthma and Immunology Annual Meeting.TX, USA, 22-26February2013."},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.9.6.722"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200721020-00005"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60197-4"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03620.x"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-006-9002-x"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0036-y"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.2165\/11587030-000000000-00000"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.06.012"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2012.04594.x"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.06.002"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anpedi.2008.11.014"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/193229681200600405"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.14.34","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:10:26Z","timestamp":1715994626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.14.34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.2217\/imt.14.34"],"URL":"https:\/\/doi.org\/10.2217\/imt.14.34","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-06-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}